Senescence-induced inflammation: an important player and key therapeutic target in atherosclerosis

Eur Heart J. 2020 Aug 14;41(31):2983-2996. doi: 10.1093/eurheartj/ehz919.

Abstract

Inflammation is a hallmark and potent driver of pathological vascular remodelling in atherosclerosis. However, current anti-inflammatory therapeutic strategies have shown mixed results. As an alternative perspective on the conundrum of chronic inflammation emerging evidence points towards a small subset of senescent cells as a critical player and central node driving atherosclerosis. Senescent cells belonging to various cell types are a dominant and chronic source of a large array of pro-inflammatory cytokines and various additional plaque destabilizing factors, being involved with various aspects of atherosclerosis pathogenesis. Antagonizing these key agitators of local chronic inflammation and plaque instability may provide a causative and multi-purpose therapeutic strategy to treat atherosclerosis. Anti-senescence treatment options with translational potential are currently in development. However, several questions and challenges remain to be addressed before these novel treatment approaches may enter the clinical setting.

Keywords: Ageing; Atherosclerosis; Cardiovascular disease; Inflammation; Vascular disease.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Atherosclerosis* / drug therapy
  • Atherosclerosis* / etiology
  • Cellular Senescence
  • Cytokines
  • Humans
  • Inflammation / drug therapy
  • Plaque, Atherosclerotic*

Substances

  • Cytokines